New Pre-Surgery treatment aims to shrink tumors, improve survival
NCT ID NCT04795661
Summary
This study is testing whether giving an immunotherapy drug called pembrolizumab before surgery is safe and effective for patients with certain localized, operable cancers that have specific genetic features (MSI/dMMR). The main goal is to see if the treatment can completely eliminate the tumor cells by the time of surgery. The trial will enroll about 240 adults with cancers like colorectal or gastric cancer that have not yet spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED RESECTABLE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hôpital Saint-Antoine
Paris, 75571, France
-
APHP Hôpital Saint-Louis
Paris, 75010, France
-
CHU Amiens Picardie
Amiens, 80054, France
-
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
-
CHU Poitiers
Poitiers, 86021, France
-
CHU Saint Etienne
Saint-Etienne, 42270, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Eugène Marquis
Rennes, 35042, France
-
Centre Georges-Francois Leclerc
Dijon, 21079, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Paul Strauss
Strasbourg, 67200, France
-
Groupe Hospitalier Diaconesses Croix Saint-Simon
Paris, 75571, France
-
Hopital Huriez
Lille, 59037, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut de cancérologie Strasbourg Europe
Strasbourg, 67200, France
-
Institut du Cancer Val d'Aurelle
Montpellier, 34298, France
-
Institut mutualiste Montsouris
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.